BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 27287458)

  • 21. Antitumor activity of YM155, a selective survivin suppressant, in combination with cisplatin in hepatoblastoma.
    Yu Y; Zhao X; Zhang Y; Kang Y; Wang J; Liu Y
    Oncol Rep; 2015 Jul; 34(1):407-14. PubMed ID: 25955434
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Silencing of survivin using YM155 induces apoptosis and chemosensitization in neuroblastomas cells.
    Liang H; Zhang L; Xu R; Ju XL
    Eur Rev Med Pharmacol Sci; 2013 Nov; 17(21):2909-15. PubMed ID: 24254560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines.
    Iwasa T; Okamoto I; Suzuki M; Nakahara T; Yamanaka K; Hatashita E; Yamada Y; Fukuoka M; Ono K; Nakagawa K
    Clin Cancer Res; 2008 Oct; 14(20):6496-504. PubMed ID: 18927289
    [TBL] [Abstract][Full Text] [Related]  

  • 24. YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation.
    Pennati M; Sbarra S; De Cesare M; Lopergolo A; Locatelli SL; Campi E; Daidone MG; Carlo-Stella C; Gianni AM; Zaffaroni N
    Int J Cancer; 2015 Jan; 136(2):299-309. PubMed ID: 24866585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. YM155 inhibits tumor growth and enhances chemosensitivity to cisplatin in osteosarcoma.
    Gao JZ; Chen FH; Wang L; Wei H; Meng SL
    Eur Rev Med Pharmacol Sci; 2015; 19(11):2062-9. PubMed ID: 26125270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An Investigation on the Therapeutic Potential of Butein, A Tretrahydroxychalcone Against Human Oral Squamous Cell Carcinoma.
    Bordoloi D; Monisha J; Roy NK; Padmavathi G; Banik K; Harsha C; Wang H; Kumar AP; Arfuso F; Kunnumakkara AB
    Asian Pac J Cancer Prev; 2019 Nov; 20(11):3437-3446. PubMed ID: 31759370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. YM155 Reverses Statin Resistance in Renal Cancer by Reducing Expression of Survivin.
    Nitta T; Koike H; Miyao T; Miyazawa Y; Kato H; Furuya Y; Sekine Y; Suzuki K
    Anticancer Res; 2017 Jan; 37(1):75-80. PubMed ID: 28011476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survivin selective inhibitor YM155 promotes cisplatin‑induced apoptosis in embryonal rhabdomyosarcoma.
    Ueno T; Uehara S; Nakahata K; Okuyama H
    Int J Oncol; 2016 May; 48(5):1847-54. PubMed ID: 26983495
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1.
    Wagner V; Hose D; Seckinger A; Weiz L; Meißner T; Rème T; Breitkreutz I; Podar K; Ho AD; Goldschmidt H; Krämer A; Klein B; Raab MS
    Oncotarget; 2014 Nov; 5(21):10237-50. PubMed ID: 25296978
    [TBL] [Abstract][Full Text] [Related]  

  • 30. YM155 sensitizes TRAIL-induced apoptosis through cathepsin S-dependent down-regulation of Mcl-1 and NF-κB-mediated down-regulation of c-FLIP expression in human renal carcinoma Caki cells.
    Woo SM; Min KJ; Seo BR; Kwon TK
    Oncotarget; 2016 Sep; 7(38):61520-61532. PubMed ID: 27528031
    [TBL] [Abstract][Full Text] [Related]  

  • 31. YM155 induces caspase-8 dependent apoptosis through downregulation of survivin and Mcl-1 in human leukemia cells.
    Feng W; Yoshida A; Ueda T
    Biochem Biophys Res Commun; 2013 May; 435(1):52-7. PubMed ID: 23618862
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma.
    Kita A; Nakahara T; Yamanaka K; Nakano K; Nakata M; Mori M; Kaneko N; Koutoku H; Izumisawa N; Sasamata M
    Leuk Res; 2011 Jun; 35(6):787-92. PubMed ID: 21237508
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Down-regulation of Akt by methanol extracts of Impatiens balsamina L. promotes apoptosis in human oral squamous cell carcinoma cell lines.
    Shin JA; Ryu MH; Kwon KH; Choi B; Cho SD
    J Oral Pathol Med; 2015 Jul; 44(6):420-8. PubMed ID: 25212570
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models.
    Nakahara T; Kita A; Yamanaka K; Mori M; Amino N; Takeuchi M; Tominaga F; Kinoyama I; Matsuhisa A; Kudou M; Sasamata M
    Cancer Sci; 2011 Mar; 102(3):614-21. PubMed ID: 21205082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interleukin enhancer-binding factor 3/NF110 is a target of YM155, a suppressant of survivin.
    Nakamura N; Yamauchi T; Hiramoto M; Yuri M; Naito M; Takeuchi M; Yamanaka K; Kita A; Nakahara T; Kinoyama I; Matsuhisa A; Kaneko N; Koutoku H; Sasamata M; Yokota H; Kawabata S; Furuichi K
    Mol Cell Proteomics; 2012 Jul; 11(7):M111.013243. PubMed ID: 22442257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
    Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
    Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuropilin-1 promotes epithelial-to-mesenchymal transition by stimulating nuclear factor-kappa B and is associated with poor prognosis in human oral squamous cell carcinoma.
    Chu W; Song X; Yang X; Ma L; Zhu J; He M; Wang Z; Wu Y
    PLoS One; 2014; 9(7):e101931. PubMed ID: 24999732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination of YM155, a survivin suppressant with a STAT3 inhibitor: a new strategy to treat diffuse large B-cell lymphoma.
    Kaneko N; Kita A; Yamanaka K; Mori M
    Leuk Res; 2013 Sep; 37(9):1156-61. PubMed ID: 23746965
    [TBL] [Abstract][Full Text] [Related]  

  • 39. YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model.
    Nakahara T; Yamanaka K; Hatakeyama S; Kita A; Takeuchi M; Kinoyama I; Matsuhisa A; Nakano K; Shishido T; Koutoku H; Sasamata M
    Anticancer Drugs; 2011 Jun; 22(5):454-62. PubMed ID: 21389848
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cyclosporine A Suppresses the Malignant Progression of Oral Squamous Cell Carcinoma in vitro.
    Gao L; Dong J; Zhang N; Le Z; Ren W; Li S; Li F; Song J; Wang Q; Dou Z; Park SY; Zhi K
    Anticancer Agents Med Chem; 2019; 19(2):248-255. PubMed ID: 30378503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.